Text Size

Changing from preserved, to preservative-free cyclosporine 0.1% enhanced triple glaucoma therapy: impact on ocular surface disease – a randomized controlled trial

Konstas A.-G., Boboridis K. G., Athanasopoulos G. P., Haidich A.-B., Voudouragkaki I. C., Pagkalidou E., Katsanos A., Katz L. J.


  • 2023
  • Eye
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    University Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Epidemiology, Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Ophthalmology, University of Ioannina, Ioannina, Greec; Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA

Related Publications

Personality Traits Associated with Treatment Choice with an Explicit Statistical Prediction After an Explanation in a Negative Context: A Study in Patients with Glaucoma

Kodaka F.; Noro T.; Kishimoto N.; Kurosawa M.; Itoh Y.; Ogawa S.; Watanabe T.; Kubota M.; Hori K.; Shigeta M.; Nakano T.


Comparative Study of Latanoprost Drug Delivery Systems for Glaucoma Treatment and Their Interaction with the Tear Film Lipid Layer Models

Saija M.C.; Vazdar K.; Pajerski W.; Olżyńska A.; Daull P.; Garrigue J.-S.; Cwiklik L.


Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022